Results 91 to 100 of about 358,966 (235)

CSF‐Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery

Annals of Neurology, EarlyView.
Objective To characterize Fc‐glycosylation profiles in patients with anti‐N‐methyl‐D‐aspartate receptor encephalitis (NMDARe) and assess their association with antibody compartmentalization (cerebrospinal fluid [CSF] vs serum), disease triggers (viral, tumor‐related or idiopathic), and 1‐year outcomes.
Laura Marmolejo, Claudia Papi, Chiara Milano, Esther Aguilar, Estibaliz Maudes, Ivana Duvnjak Orešković, Jerko Štambuk, Maja Pučić‐Baković, Gemma Olivé‐Cirera, Elianet Fonseca, Mar Guasp, Eugenia Martinez‐Hernandez, Helena Ariño, Takahiro Iizuka, Thais Armangué, Josep Dalmau, Marianna Spatola   +16 more
wiley   +1 more source

Neuropsychiatry as a paradigm propelling neurology and psychiatry into the future

BJPsych Open
Neurology and psychiatry have long been divided as subspecialities of medicine. However, the symptom overlap in central nervous system illness is unmistakable.
Jay A. Salpekar, Marco Mula, Niruj Agrawal, Kenneth R. Kaufman   +3 more
doaj   +1 more source

Increased Numbers of CD4+ T‐Cells in the Hypocretin/Orexin Region of Narcolepsy Type 1

Annals of Neurology, EarlyView.
Narcolepsy type 1 (NT1) is presumed to be an autoimmune disorder caused by hypothalamic loss of hypocretin (Hcrt; orexin). In postmortem NT1 brains, we observed an 11‐fold increase of CD4+ T‐cells in the Hcrt region compared with control hypothalami, without a corresponding rise in CD8+ T‐cells.
Ling Shan, Milo Fonville, Mabel Hoekstra, Rolf Fronczek, Joost Smolders, Dick F. Swaab   +5 more
wiley   +1 more source

Chronic post-COVID neuropsychiatric symptoms persisting more than 1 year after infection during the ‘Omicron wave’

BJPsych Open
Background The heterogeneity of chronic post-COVID neuropsychiatric symptoms (PCNPS), especially after infection by the Omicron strain, has not been adequately explored.
Steven Wai Ho Chau, Timothy Mitchell Chue, Tsz Ching Lam, Yee Lok Lai, Rachel Ngan Yin Chan, Paul W. C. Wong, Shirley Xin Li, Yaping Liu, Joey Wing Yan Chan, Paul Kay-sheung Chan, Christopher Koon-Chi Lai, Thomas W. H. Leung, Yun Kwok Wing   +12 more
doaj   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by increased Type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Whither Neuropsychiatry? [PDF]

Journal of Neuropsychiatry, 2005
openaire   +2 more sources

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Clinical Neuropsychiatry

Focus, 2016
Margo, Lauterbach, Sheldon, Benjamin
openaire   +3 more sources

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays

Arthritis &Rheumatology, Accepted Article.
Objective Cardiac involvement is a major cause of morbidity in systemic lupus erythematosus (SLE). Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is elevated in SLE, but its contribution to lupus‐associated cardiac injury is unclear. We investigated the role of TWEAK/Fn14 signaling in SLE‐related cardiomyopathy and its potential as a ...
Yale Liu, Zhu Yan, Xueting Peng, Meixuan Li, Juan Wang, Yan Zhang, Xiaoqian Hu, Mingzhu Zhou, Kaixuan Ren, Dan Zhang, Xingyi Guo, Yumin Xia, Huanhuan Huo   +12 more
wiley   +1 more source